Published in Except Child on October 01, 1988
Four fallacies of segregationism. Except Child (1988) 0.79
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Neopterin as a marker for immune system activation. Curr Drug Metab (2002) 2.25
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Immune activation and psoriasis. Lancet (1991) 1.93
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (2001) 1.63
Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J (1993) 1.61
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem (1989) 1.59
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med (2000) 1.51
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
Altered iron metabolism and the anemia of chronic disease: a role of immune activation. Blood (1992) 1.39
Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem (1993) 1.35
Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34
Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J Virol (2001) 1.33
Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res (2003) 1.32
Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J (1989) 1.31
Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem (2003) 1.31
Effects of systematic formative evaluation: a meta-analysis. Except Child (1986) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol (1996) 1.27
The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. J Virol (1999) 1.26
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology (2000) 1.20
Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta (1989) 1.19
Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol (1992) 1.17
Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis (1993) 1.17
Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem (2010) 1.16
Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS). A preliminary report. Hoppe Seylers Z Physiol Chem (1983) 1.14
Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett (1993) 1.14
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Determination of neopterin in serum and urine. Clin Chem (1987) 1.12
Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest (2003) 1.12
Linkage of cell-mediated immunity to iron metabolism. Immunol Today (1995) 1.11
Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab (2008) 1.11
Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol (1997) 1.09
Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology (1992) 1.09
Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int (2006) 1.08
Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler (1989) 1.08
Decreased plasma tryptophan in pregnancy. Obstet Gynecol (1996) 1.08
Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm (Vienna) (2000) 1.08
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr (1994) 1.07
CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol (2008) 1.07
Who will get AIDS? Lancet (1986) 1.07
Do students with and without lexical retrieval weaknesses respond differently to instruction? J Learn Disabil (2004) 1.07
Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med (2001) 1.06
Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res (2009) 1.05
Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res (1999) 1.04
Simultaneous determination of neopterin and creatinine in serum with solid-phase extraction and on-line elution liquid chromatography. Clin Chem (1987) 1.04
Recovery of muscles of old rats after hindlimb immobilisation by external fixation is impaired compared with those of young rats. Exp Gerontol (2001) 1.03
Posttransplant neopterin excretion in renal allograft recipients--a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation (1991) 1.03
Tryptophan degradation to control T-cell responsiveness. Immunol Today (2000) 1.03
Neopterin as an index of immune response in patients with tuberculosis. Lung (1984) 1.02
In vivo activation of CD4+ cells in AIDS. Science (1987) 1.02
Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res (1990) 1.01
Urinary neopterin: an early marker of HIV infection. Eur J Clin Microbiol (1987) 1.01
Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol (1999) 1.01
Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation (1984) 1.01
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol (1998) 1.01
Potential of urinary neopterin excretion in differentiating chronic non-A, non-B hepatitis from fatty liver. Lancet (1987) 1.00
[Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors]. Dtsch Med Wochenschr (1989) 0.99
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin Exp Immunol (2002) 0.99
Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum (1986) 0.99
Microbial translocation in simian immunodeficiency virus (SIV)-infected rhesus monkeys (Macaca mulatta). J Med Primatol (2010) 0.99
Chronic immune activation underlies morbid obesity: is IDO a key player? Curr Drug Metab (2007) 0.99
Ca2+/calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180. Biochem J (1993) 0.98
Immune reaction links disease progression in cancer patients with depression. Med Hypotheses (2000) 0.98
Association between insulin resistance, body mass and neopterin concentrations. Clin Chim Acta (1999) 0.98
Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun (2008) 0.97
Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol (2000) 0.97
Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res (2008) 0.97
Neopterin activates transcription factor nuclear factor-kappa B in vascular smooth muscle cells. FEBS Lett (1996) 0.97
Interferon-gamma-induced degradation of tryptophan by human cells in vitro. Biol Chem Hoppe Seyler (1987) 0.96
Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res (2009) 0.96
Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol (2000) 0.96
Increased cerebrospinal fluid protein tau concentration in neuro-AIDS. J Neurol Sci (1999) 0.96
Cigarette smoking: a modifier of human immunodeficiency virus type 1 infection? J Acquir Immune Defic Syndr (1991) 0.96
Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab (2000) 0.96
Enteropathy in Zambians with HIV related diarrhoea: regression modelling of potential determinants of mucosal damage. Gut (1997) 0.95
Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol (2010) 0.95
Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett (1994) 0.95
Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis (1994) 0.95
Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp (Warsz) (2000) 0.95
Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids (2007) 0.95
Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis. Lung (1997) 0.94
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm (Vienna) (2002) 0.94
Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J Thorac Cardiovasc Surg (1993) 0.94